Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 22087587)

1.

Use of venlafaxine in psychiatric disorders and climacteric syndrome: is a therapeutic bridge?

Luisi S, Castrogiovanni A, Ciani V, Pacchierotti C, Capua AD, Pasquini R, Lazzeri L, Petraglia F.

Gynecol Endocrinol. 2012 Jan;28(1):68-71. doi: 10.3109/09513590.2011.588755. Epub 2011 Nov 16.

PMID:
22087587
2.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
3.
4.
5.
6.

Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors.

Sáiz-Ruiz J, Ibáñez A, Díaz-Marsá M, Arias F, Padín J, Martín-Carrasco M, Montes JM, Ferrando L, Carrasco JL, Martín-Ballesteros E, Jordá L, Chamorro L.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Oct;26(6):1129-34.

PMID:
12452535
7.

A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.

Mazeh D, Shahal B, Aviv A, Zemishlani H, Barak Y.

Int Clin Psychopharmacol. 2007 Nov;22(6):371-5.

PMID:
17917556
8.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
10.

[Treatment with venlafaxine extended release for climacteric women with depression or anxiety diagnosis. An open-label study].

Iglesias C, Pato E, Ocio S, Ortigosa JC, Santamarina S, Merino MJ, Alonso MJ, Fernández L, Alonso JL, Rodríguez L.

Actas Esp Psiquiatr. 2009 May-Jun;37(3):137-42. Spanish.

11.

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

Rickels K, Pollack MH, Sheehan DV, Haskins JT.

Am J Psychiatry. 2000 Jun;157(6):968-74.

PMID:
10831478
12.

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.

J Clin Psychiatry. 2006 Jan;67(1):72-80.

PMID:
16426091
13.

Venlafaxine: a 2003 update.

Gutierrez MA, Stimmel GL, Aiso JY.

Clin Ther. 2003 Aug;25(8):2138-54. Review.

PMID:
14512125
14.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
15.
16.

Patient outcomes with education, drug therapy, and support: a study of venlafaxine ER-treated outpatients with major depressive disorder.

Lobello K, Reddy S, Musgnung J, Pedersen R, Ninan PT.

Psychopharmacol Bull. 2010;43(2):28-44.

PMID:
21052041
17.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
19.
20.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk